Integrated Platform Delivers Comprehensive eClinical Risk Based Monitoring Solution
MINNETONKA, MN and HOUSTON, TX May 19, 2016 -- MedNet Solutions, an innovative SaaS-based eClinical technology company that supports the entire spectrum of clinical research, and Algorics, a provider of cloud-based clinical analytics solutions and software for the global life sciences industry, today unveiled their strategic technology partnership designed to provide superior risk based monitoring (RBM) functionality to MedNet's customers around the world. Specifically, the companies have seamlessly integrated
iMedNet
, MedNet Solutions' flexible, affordable and easy-to-use eClinical platform with
Acuity
, Algorics' regulatory-compliant cloud-based clinical data analytics solution for the risk management of clinical trials. The partnership builds upon iMedNet's existing functionality to provide additional capabilities, including risk assessment and categorization tools, visualization of key risk indicators (KRIs), automated risk alerts, and actionable decision support tools that help clinical teams focus on risks that really matter. These capabilities, which are available today and can be customized to the unique needs of any research initiative, allow study sponsors and Clinical Research Organizations (CROs) to more effectively manage trial performance by providing them with real-time insights into each clinical study, helping to ensure superior safety, quality and compliance. "We are incredibly excited about our partnership with Algorics," remarked M. Clareece West, Chief Operating Officer at MedNet Solutions. "With the growing importance that RBM plays in clinical research, we now have robust and highly-configurable options for our customers that want more comprehensive RBM support. By integrating our two platforms, we can better help study sponsors maximize resource efficiency while minimizing operational costs and mitigating overall study risks." "Today's sophisticated clinical trial protocols generate ever-increasing amounts of complex data," said Rob Nichols, Chief Commercial Officer at Algorics. "This makes it extremely important to understand that data on an ongoing basis and take action against vulnerabilities in real-time. The partnership between Algorics and MedNet integrates the power of two platforms (iMedNet and Acuity) to deliver customers immediate insight into understanding their risk, and allows prioritizing and implementing remediation efforts in a meaningful and effective way."
About MedNet Solutions
MedNet Solutions is a leading healthcare technology company specializing in electronic data solutions designed for the global life sciences community. MedNet's proven, flexible and easy-to-use cloud-based eClinical systems dramatically improve the efficiency of clinical studies and registries of all types and sizes. Beyond simply electronic data capture (EDC), MedNet's solutions deliver the tools and dashboards required to expertly manage all aspects of clinical research. Since 2001, pharmaceutical, medical device, biotechnology and Contract Research Organizations (CROs) around the world have trusted MedNet to consistently deliver the technology innovation, experience and reliability they need for success. For more information, please visit us at
www.mednetstudy.com
.
About Algorics
Algorics brings together a team of highly experienced software and life sciences professionals, united behind a single goal: to provide innovative clinical analytics solutions and software to the global life sciences industry with consistent and reliable quality. Algorics has a truly international presence, with offices in Houston, TX (USA), London (UK) and Bangalore (India). Learn more by visiting
www.algorics.com
.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.